Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
Roberto Buonaiuto(Scuola Superiore Meridionale), Carmine De Angelis(Baylor College of Medicine), Aldo Caltavituro(University of Naples Federico II), Jole Ventriglia(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Neola(University of Naples Federico II), Giancarlo Troncone(Federico II University Hospital), Grazia Arpino(University of Naples Federico II), Mario Giuliano(Regione Campania), Amedeo Cefaliello(University of Naples Federico II), Francesco Pepe(Federico II University Hospital), Alessandra Longobardi(Federico II University Hospital), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Rosaria Lamia(Federico II University Hospital), Federica P. Mangiacotti(Federico II University Hospital), Umberto Malapelle(Federico II University Hospital)
Cited by 9
Related Papers
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413